Table 4.

Effects of treatment duration, vitamin D types, baseline thyroid function, and vitamin D levels on the efficacy of vitamin D therapy in HT.

	Included trials	Weight%	SMD (95% CI)	P value	I2%	Meta-regression P value
TPO-Ab
Duration of vitamin D supplementation
≤12 wk	6[31,34,36,44,49,51]	50.45	−0.454 (−0.749, −0.160)	.002	50.5	.03
>12 wk	6[33,45–48,51]	49.55	−1.741 (−2.750, −0.732)	.001	95.1
Type of vitamin D
Naive vitamin D (vitamin D2 or D3)	4[33,36,44,49]	34.60	−0.300 (−0.566, −0.034)	.027	35.2	.046
Calcitriol	8[31,34,45–48,50,51]	65.40	−1.522 (−2.277, −0.766)	<.001	92.4
Baseline thyroid function
Euthyroidism/Subclinical hypothyroidism	5[33,34,44,45,49]	43.13	−0.644 (−1.03, −0.252)	.001	74.8	.27
Hypothyroidism	7[31,36,46–48,50,51]	56.87	−1.420 (−2.415, −0.426)	.005	94.7
Baseline 25(OH)D levels
Not restricted	3[31,47,50]	24.77	−1.342 (−2.685, 0.000)	.05	93.9	.97
Insufficiency	4[33,34,48,51]	33.03	−0.713 (−1.139, −0.287)	.001	56.5
Deficiency	5[36,44–46,49]	42.20	−1.215 (−2.297, −0.132)	.03	95.9
TG-Ab
Duration of vitamin D supplementation
≤12 wk	5[31,34,44,49,51]	45.70	−0.420 (−0.683, −0.156)	.002	29.3	.09
>12 wk	6[33,45–48,50]	54.30	−1.475 (−2.505, −0.446)	.005	95.5
Type of vitamin D
Naive vitamin D (vitamin D2 or D3)	3[33,44,49]	28.36	−0.138 (−0.505, 0.229)	.46	60.1	.06
Calcitriol	8[31,34,45–48,50,51]	71.64	−1.341 (−2.045, −0.637)	<.001	91.5
Baseline thyroid function
Euthyroidism/subclinical hypothyroidism	5[33,34,44,45,49]	46.86	−0.400 (−0.783, −−0.017)	.04	74.4	.06
Hypothyroidism	6[31,46–48,50,51]	53.14	−1.513 (−2.469, −0.557)	.002	93.0
Baseline 25(OH)D Levels
Not restricted	3[31,47,50]	26.72	−1.755 (−3.184, −0.325)	.02	94.0	.49
Insufficiency	4[33,34,48,51]	36.12	−0.373 (−0.831, 0.085)	.11	64.0
Deficiency	4[44–46,49]	37.16	−1.043 (−2.076, −0.010)	.048	95.1
FT4
Duration of vitamin D supplementation
≤12 wk	5[31,34,44,49,51]	50.10	0.022 (−0.190, 0.234)	.84	0.0	<.001
>12 wk	5[33,46–48,50]	49.90	1.388 (0.756, 2.201)	<.001	86.4
Type of vitamin D
Naive vitami> D (vitamin D2 or D3)	3[33,44,49]	31.17	0.274 (−0.448, 0.997)	.46	89.3	.26
Calcitriol	7[31,34,46–48,50,51]	68.83	0.940 (0.241, 1.639)	.008	90.8
Baseline thyroid function
Euthyroidism/subclinical hypothyroidism	4[33,34,44,49]	41.38	0.240 (−0.289, 0.769)	.37	84.1	.10
Hypothyroidism	6[31,46–48,50,51]	58.62	1.080 (0.343, 1.817)	.004	89.7
Baseline 25(OH)D Levels
Not restricted	3[31,47,50]	29.67	1.264 (0.297, 2.231)	.01	89.0	.39
Insufficiency	4[33,34,48,51]	39.44	0.433 (−0.061, 0.927)	.09	69.0
Deficiency	3[44,46,49]	30.89	0.642 (−0.687, 1.971)	.34	96.4
FT3
Duration of vitamin D supplementation
≤12 wk	5[31,34,44,49,51]	49.92	−0.052 (−0.264, 0.169)	.63	0.0	<.001
>12 wk	5[33,46–48,50]	50.08	1.107 (0.536, 1.677)	<.001	84.7
Type of vitamin D
Naive vitamin D (vitamin D2 or D3)	3[33,44,49]	31.53	0.098 (−0.226, 0.422)	.55	49.0	.18
Calcitriol	7[31,34,46–48,50,51]	68.47	0.750 (0.116, 1.384)	.02	89.4
Baseline thyroid function
Euthyroidism/subclinical hypothyroidism	4[33,34,44,49]	41.76	0.029 (−0.246, 0.304)	.83	42.7	.02
Hypothyroidism	6[31,46–48,50,51]	58.24	0.926 (0.339, 1.513)	.002	84.6
Baseline 25(OH)D levels
Not restricted	3[31,47,50]	29.65	1.018 (0.139, 1.898)	.02	87.5	.44
Insufficiency	4[33,34,48,51]	39.13	0.200 (−0.129, 0.529)	.23	33.4
Deficiency	3[44,46,49]	31.22	0.532 (−0.558, 1.622)	.34	95.0